Table 1 Comparative analysis of characteristics between patients with and without HT.

From: The value of the CRP-albumin-lymphocyte index (CALLY index) as a prognostic biomarker in acute ischemic stroke

 

Total (n = 439)

Non-HT (n = 396)

HT (n = 43)

P value

Demographics

Male, no. (%)

311 (70.8)

278 (70.2)

33 (76.7)

0.370

Age (IQR), y

64 (55–71)

64 (55–71)

65 (56–72)

0.391

Medical history and risk factor

Current smoking, no. (%)

243 (55.4)

216 (54.5)

27 (62.8)

0.302

Current drinking, no. (%)

171 (39.0)

150 (37.9)

21 (48.8)

0.162

Hypertension, no. (%)

319 (72.7)

290 (73.2)

29 (67.4)

0.418

Dyslipidemia, no. (%)

174 (39.6)

157 (39.6)

17 (39.5)

0.989

Diabetes mellitus, no. (%)

144 (32.8)

129 (32.6)

15 (34.9)

0.759

Atrial fibrillation, no. (%)

93 (21.2)

78 (19.7)

15 (34.9)

0.021

Prior stroke, no. (%)

70 (15.9)

66 (16.7)

4 (9.3)

0.210

Treatment status

IVT, no. (%)

67 (15.3)

54 (13.7)

13 (31.0)

0.004

NIHSS on admission (IQR)

4 (2–8)

4 (2–8)

7 (3–10)

0.015

Baseline SBP (IQR), mmHg

145 (133–160)

145.5 (133–160)

141 (131–155)

0.326

Baseline DBP (IQR), mmHg

84 (76–92)

84 (76–93)

82 (74–90)

0.068

With infection diseases, no. (%)

157 (35.8)

140 (33.7)

25 (58.1)

0.002

TOAST subtypes, no. (%)

< 0.001

LAA

266 (61.0)

243 (61.8)

23 (53.5)

 

CE

40 (9.2)

27 (6.9)

13 (30.2)

 

SAO

59 (13.5)

57 (14.5)

2 (4.7)

 

Other determined

9 (2.1)

9 (2.3)

0 (0.0)

 

Undetermined

62 (14.2)

57 (14.5)

5 (11.6)

 

Laboratory data

LDL (IQR), mmol/L

3.03 (2.47–3.60)

3.03 (2.48–3.60)

2.97 (2.395–3.625)

0.855

HDL (IQR), mmol/L

1.08 (0.91–1.26)

1.07 (0.91–1.26)

1.10 (0.93–1.26)

0.542

TC (IQR), mmol/L

4.76 (3.97–5.52)

4.76 (4.00-5.49)

4.59 (3.75–5.60)

0.723

TG (IQR), mmol/L

1.56 (1.09–2.26)

1.58 (1.09–2.27)

1.31 (1.00-2.28)

0.692

Creatine (IQR), umol/L

77.0 (63.8–91.8)

77.1 (62.6–92.0)

76.4 (67.2–86.0)

0.483

PLT (IQR), 109/L

204 (170–242)

205 (169.25–242)

203 (171–245)

0.688

Leukocyte (IQR), 109/L

7.2 (6.0-8.9)

7.1 (5.9–8.7)

8.4 (7.6–9.8)

0.005

Lymphocyte (IQR), 109/L

1.5 (1.1–1.9)

1.5 (1.1–1.9)

1.2 (1.0-1.5)

0.002

Neutrophil (IQR), 109/L

5.0 (3.8–6.7)

4.8 (3.7–6.5)

6.5 (5.1-8.0)

< 0.001

BG (IQR), mmol/L

6.73 (5.52–9.20)

6.75 (5.50–9.19)

6.50 (5.60–9.63)

0.373

CRP (IQR), mg/L

4.63 (2.57–11.40)

4.22 (2.50-10.22)

10.10 (5.96–33.60)

0.001

Albumin (IQR), g/L

39.1 (36.5–41.3)

39.1 (36.3–41.3)

39.7 (36.9–41.8)

0.527

CALLY (IQR)

1.17 (0.48–2.35)

1.36 (0.56–2.50)

0.47 (0.14–0.89)

< 0.001

Imaging data

    

HMCA sign, no. (%)

6 (1.4)

4 (1.0)

2 (4.7)

0.207

ASPECTS (IQR)

9.0 (8.0–10.0)

9.0 (8.0–10.0)

7.0 (6.0–8.0)

< 0.001

Infarct volume (IQR), cc

5.0 (1.9–19.6)

3.6 (1.5–10.0)

39.3 (13.1–80.0)

< 0.001

Early infarct signs on admission

CT head scan, no. (%)

287 (65.4)

244 (61.6)

43 (100.0)

< 0.001

Model Scoring

HTI (IQR)

0.00 (0.00–1.00)

0.00 (0.00–1.00)

0.00 (1.00–2.00)

< 0.001

HeRS (IQR)

0.13 (0.10–0.18)

0.12 (0.106–0.17)

0.20 (0.13–0.27)

< 0.001

SPAN-100 (IQR)

70.0 (60.0–78.0)

69.0 (60.0–78.0)

73.0 (64.0–82.0)

0.072

GRASPS (IQR)

51.0 (47.0–55.0)

51.0 (47.0–55.0)

51.0 (47.0–55.0)

0.626

HAT (IQR)

1.00 (1.00–2.00)

1.00 (0.00–2.00)

1.00 (1.00–2.00)

< 0.001

SEDAN (IQR)

1.00 (1.00–2.00)

1.00 (1.00–2.00)

2.00 (1.00–3.00)

0.003

  1. The above data is described in terms of counts (proportions) or medians (P25-P75).
  2. CALLY, Albumin×Lymphocytes/(10×CRP); LDL, low-density lipoprotein; HDL, high-density lipoprotein; TC, total cholesterol; TG, triglycerides; PLT, platelet; BG, blood glucose; CRP, C-reactive protein; IVT, Intravenous thrombolysis; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; DBP, diastolic blood pressure; TOAST, Trial of Org 10,172 in Acute Stroke Treatment; LAA, large-artery atherosclerosis; CE, cardio embolism; SAO, small-arterial occlusion. HMCA sign, High-Density Middle Cerebral Artery Sign; ASPECTS, Alberta Stroke Program Early CT Score; HTI, the Hemorrhagic Transformation Index score; HeRS, Hemorrhage Risk Stratification score; SPAN-100, Stroke Prognostication using Age and NIHSS score; GRASPS, GWTG-Stroke sICH risk score; HAT, Hemorrhage After Thrombolysis score; SEDAN, Symptomatic Intracranial Hemorrhage after Stroke Thrombolysis score.
Back to article page